– USA, MA – Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced the appointment of Keli Walbert to its Board of Directors, effective immediately, bringing more than two decades of biopharmaceutical commercial leadership experience.
“We are delighted to welcome Keli to the Apellis Board of Directors. Keli has a proven track record of successfully bringing novel medicines to patients as well as a respected reputation among industry leaders for her strategic thinking and innovation. Her deep commercial expertise will be invaluable as we continue to reach more patients with geographic atrophy and prepare for a potential launch in C3G and IC-MPGN,” said CEO and co-founder, Dr. Cedric Francois.
About Keli Walbert
Keli Walbert most recently served as EVP, U.S. Commercial, at Horizon Therapeutics, where she drove commercial strategy and organizational development for more than 10 marketed brands across nephrology, ophthalmology, and rare diseases. Previously, she held leadership roles at AbbVie, American Medical Association, Abbott, and United Healthcare. Kelly Walbert led the launch of the blockbuster medicine TEPEZZA for thyroid eye disease. She holds a master’s degree from Northwestern University and a bachelor’s degree from the University of Louisville.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. The company introduced the first new class of complement medicine in 15 years and now has two approved medicines targeting C3, including the first-ever therapy for geographic atrophy, a leading cause of blindness around the world.
For more, visit www.apellis.com.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.